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ABSTRACT   
Background 
The NLST reported a significant 20% reduction in lung cancer mortality with three annual 
low-dose CT (LDCT) screens and the Dutch-Belgian NELSON trial indicates a similar 
reduction. We present the results of UKLS trial.  
Methods 
From October 2011 to February 2013, we randomly allocated 4 055 participants to either a 
single invitation to screening with LDCT or to no screening (usual care). Eligible participants 
(aged 50-75) had a risk score (LLPv2) ≥4·5% of developing lung cancer over five years. Data 
were collected on lung cancer cases and deaths to 29 February 2020 through linkage to 
national registries. The primary outcome was mortality due to lung cancer. We included our 
results in a random-effects meta-analysis to provide a synthesis of the latest randomised trial 
evidence. 
Findings 
1 987 participants in the intervention and 1 981 in the usual care arms were followed for a 
median of 7·3 years (IQR 7·1-7·6), 86 cancers were diagnosed in the LDCT arm and 75 in 
the control arm. 30 lung cancer deaths were reported in the screening arm, 46 in the control 
arm, (relative rate 0·65 [95% CI 0·41-1·02]; p=0·062). The meta-analysis indicated a 
significant reduction in lung cancer mortality with a pooled overall relative rate of 0·84 (95% 
CI 0·76-0·92) from nine eligible trials. 
Interpretation 
The UKLS trial of single LDCT indicates a reduction of lung cancer death of similar 
magnitude to the NELSON and NSLT protocols and was included in a meta-analysis of nine 
randomised trials which provides unequivocal support for lung cancer screening in identified 
risk groups.   
Funding 
NIHR Health Technology Assessment programme; NIHR Policy Research programme; Roy 






INTRODUCTION   
Lung cancer screening trials were initiated in the 1970s 1,2 based on chest X-rays and sputum 
analysis, however, there was no evidence of any mortality advantage. The first low dose 
computed tomography (LDCT) screening was undertaken in Japan3 and later the potential of 
utilising LDCT screening was published in a landmark paper from the Early Lung Cancer 
Action Project (ELCAP) in 1999.4  Two large LDCT screening trials have provided evidence 
of a statistically significant reduction in lung cancer mortality in the individuals recruited in 
the LDCT screening arm;5,6 NLST also reported a small but significant reduction in overall 
mortality. 5  In the US, lung cancer screening has been recommended by the United States 
Preventive Services Task Force (USPSTF).7-9 Six LDCT screening trials have been 
undertaken in Europe, which have already published their mortality data,6,10-14 as well as 
programmes in Canada15 Japan 16 and Korea.17 
The largest randomised trials, the US National Lung Screening Trial (NLST) and the Dutch-
Belgian Lung Cancer Screening Trial (NELSON), have provided conclusive evidence that the 
intervention reduces lung cancer mortality, so that we should now seriously consider 
implementation of lung cancer CT screening in Europe and the rest of the world.18-20  
The UKLS trial of 4 055 individuals was undertaken from 2011 to 201321,22 and in this paper, 
we report on incidence and mortality outcomes for 3 968 with cancer registry and mortality 
data available.  We also undertook a meta-analysis of the randomised, controlled LDCT 





UKLS was a randomised controlled trial, comparing LDCT screening with usual care using 
the “Wald Single-Screen” design21. The UKLS trial is unique in its design being a single 
LDCT screening in a high-risk population. The UKLS is a RCT of LDCT compared with 
usual care, for the early detection of lung cancer. The methods for the UKLS pilot study were 
derived from an initial feasibility study and follow the Wald Single-Screen Design.  Other 
screening trials have used this design, including the UK Flexisig Trial, the UK Aortic 





The study was based in two thoracic hospitals in the United Kingdom, the Liverpool Heart 
and Chest Hospital, on Merseyside, and Royal Papworth Hospital, in Cambridgeshire. Ethical 
approval was received from the Liverpool Central Research Ethics Committee (reference 
10/H1005/74). Trial registration: International Standard Randomised Controlled Trial 
Register (reference 78513845).  Full details of the design and protocol have been described 
elsewhere.21  
Participants 
To recruit participants with a high risk of developing lung cancer from a target population 
broadly representative of the UK population, an initial invitation letter, UKLS participant 
information sheet and questionnaire were sent to individuals aged 50-75 living in specific 
primary care trusts (PCTs) in the vicinity of the two hospital sites.21 
For those individuals who returned completed questionnaires, the responses were analysed to 
identify those at high risk of developing lung cancer over the next five years defined as a risk 
score of 4·5% as per version 2 of the validated Liverpool Lung Project risk model 
(LLPv2).23,24 Factors contributing to the LLP risk score are highlighted in Table 1. A second 
questionnaire was sent to these individuals and the following exclusion criteria applied: 
inability to give consent, or any condition precluding written informed consent; any 
comorbidity which would unequivocally contraindicate either screening or treatment if lung 
cancer were to be detected; a chest CT performed within the preceding year; inability to lie 
flat. Those remaining eligible were invited to attend a clinic at one of the recruitment centres, 
where written informed consent was obtained. 
Randomisation and masking 
Eligible, consenting individuals who attended a clinic were randomised at a ratio of 1:1 into 
the intervention arm (LDCT) or the no screening control arm (usual care). Randomisation 
was stratified by trial site and took place outside of the clinic and after the individuals had left 
the clinic using a two-stage computer algorithm with an automated procedure. This ensured 
allocation concealment from the clinic staff. Further technical details are given by Field et 
al.21 Due to the nature of the intervention, blinding of the participants and screening staff 
thereafter was not possible, and participants were informed of which group they were in 
within two weeks after randomisation.  However, outcomes were determined without 
knowledge of trial allocation, since these came from routine cancer registration and death 





The LDCT subjects received a baseline scan (16+ channel multi-detector CT, no contrast, 
100-140 kVp) and nodules were assessed by two local radiologists (Liverpool Heart and 
Chest Hospital or Papworth Hospital) and placed in one of four pre-defined nodule 
categories: Category 4 (large), Category 3 (medium), Category 2 (small), Category 1 
(other)21,25 (Supplementary material, Figure 2). Consensus nodule category was assigned 
following central reading at the Royal Brompton Hospital, with a read for arbitration when 
necessary. Category 4 nodules were immediately referred to participating MDT clinic for 
work-up and clinical management. Category 3 nodules identified in the baseline scan were 
reanalysed in follow-up CT scans at three and twelve months; Category 2 nodules at twelve 
months only. Growth of nodules was based on their characteristics and volume doubling time 
(VDT); i.e. VDT <400 days or new solid component of non-solid nodule was classified as 
growth in the UKLS trial and were referred to the trial participating MDT clinic for work-up 
and clinical management.21,26 Subjects with nodules that resolved were discharged and those 
with stable nodules were further monitored according to local practice. 
Outcomes 
Outcomes from UK cancer and death registry data were provided by NHS Digital and the 
National Cancer Registration and Analysis Service (NCRAS) who were not aware of the 
participants’ allocated trial arm. The follow-up period for mortality was up to 29 February 
2020 (last death recorded ONS mortality data), and for incidence of lung cancer was up to 31 
December 2019 (data from: NCRAS to March 2018; NHS Digital Cancer Registration data to 
Feb 2019; cause of death from ONS mortality data up to December 2019). 
The primary outcome in this analysis was mortality due to lung cancer. This was defined as a 
death during the follow-up period where lung cancer was listed as the underlying cause of 
death in the UK civil registrations data provided by NHS Digital (ONS mortality data). 
Secondary outcomes investigated for all participants were mortality from all causes, mortality 
from all cancers, mortality from causes other than lung cancer, and lung cancer incidence. 
Secondary outcomes for those diagnosed with lung cancer were all-cause mortality, mortality 
from causes other than lung cancer, and the distributions of the stage and histological type of 
the diagnosed cancers. Stage and histology were provided by NCRAS. 
Lung cancer incidence was investigated and compared by baseline CT scan result using the 




Differences between males and females were investigated for the primary outcome, for lung 
cancer incidence, for all-cause mortality in those diagnosed with lung cancer, and for stage 
distribution.  
Statistical analysis 
The primary outcome to be compared between intervention and control groups was lung 
cancer mortality. Sample size calculations, as set out in the study protocol, stated that for a 
relative risk of lung cancer mortality of 0·69 after three years, based on a single screen 
intervention, with 90% power to detect a significant difference with 2-sided testing at the 5% 
level, and allowing for a compliance rate of 80%, it was determined that 16 000 participants 
would need to be recruited into each arm. For the pilot stage, the target recruitment total was 
4 000 participants (2 000 in each arm). The study did not proceed beyond the pilot stage, and 
hence the data presented here are not powered to detect significant mortality benefits.  
Mortality data were analysed by trial arm using Poisson regression for the purposes of 
significance testing, and to produce estimates of relative rates and 95% confidence intervals. 
The Nelson-Aalen method was used to produce cumulative hazard estimates. Incidence data 
were analysed in the same way. Differences in stage distribution and in histological type were 
assessed using Pearson’s chi-squared.  
Analyses were carried out on an intention-to-treat basis. Differences in lung cancer mortality 
were also conducted on a per-protocol basis excluding those allocated to the screening arm 
who did not undergo CT screening.  
The pilot study was not powered for a reduction in lung cancer mortality, accordingly a meta-
analysis of randomised controlled trials of LDCT screening was also undertaken. This 
included randomised trials published up to 2nd November 2020, with at least 3 years median 
follow up  on the basis that true underlying differences in the lung cancer mortality would be 
very unlikely to become apparent earlier than this due to the effects of lead time, based on 
Chjen and Chen’s  publication on mean sojourn time and effectiveness of mortality reduction 
for lung cancer screening with computed tomography.27  The “metan” suite of commands in 
Stata was used to produce a summary risk ratio of the effect of invitation to LDCT screening 
on the most recently published lung cancer mortality and all-cause mortality.  A random 
effects model was assumed with heterogeneity reported using the chi-squared test and I2 
statistic. The overall effect of LDCT screening on lung cancer mortality was explored by sex 




The Statistical Analysis Plan for UKLS and the meta-analysis is provided in the 
Supplementary Appendix (pages 1-11) and was signed off prior to comparative analysis. All 
statistical analyses were carried out using Stata, version 16.1. 
The trial was registered with the International Standard Randomised Controlled Trial 
Register (reference 78513845). 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
 
RESULTS 
Postal invitations were sent to 247 354 individuals in two separate tranches, between August 
2011 and March 2012, and between May 2012 and August 2012. Of 75 958 who responded 
positively, 8 729 were deemed to fall into the high-risk category. Of these, 5 967 responded 
positively to the second questionnaire, of whom 4 868 were invited to attend a clinic at a 
recruitment centre. A total of 4 152 attended a clinic between 17 October 2011 and 22 
February 2013, of whom 4 061 gave written informed consent. Six consenting individuals 
were excluded before randomisation; of the remaining 4 055 participants, 2 028 were 
randomised into the intervention arm (screening) and 2 027 into the control arm (usual care).  
Subsequent to randomisation, it was identified that 56 individuals (30 in the intervention arm 
and 26 in the control arm) had not provided consent for their data to be linked for follow-up. 
A further 31 (11 in the intervention arm and 20 in the control arm) were identified as having 
undergone censoring events before they had given consent. All 87 of these individuals were 
excluded from the analysis, leaving a total of 3 968 participants (1 987 in the intervention 
arm and 1 981 in the control arm). See Figure 1 for further details.  
Baseline characteristics of the participants who were randomised were balanced as shown in 
Table 1. Of those allocated to the screening arm, 1 954 received a baseline CT scan and 33 
did not (for reasons including withdrawal of consent and change in health condition); these 
33 were included in our intention-to-treat analysis but excluded from the per-protocol 
analysis. From 1994 subjects receiving a baseline scan, LDCT screening identified 42 cancers 




baseline or follow-up scans (a false positive rate of 3.6%).21,22 We now report 3 false 
negatives (defined as cancers detected within a year of their last negative UKLS LDCT scan), 
a false negative rate of 6.7%. Over 7.2 years follow-up lung cancers were diagnosed at a rate 
of 4.3% (86/1987) in the LDCT arm and 3.8% (75/1981) in the control arm. These rates are 
significantly lower than the median risk provided by the LLPv2 risk model (>7%, Table 1), in 
keeping with the overestimation corrected in the recalibrated LLPv3 risk score.23 
Mortality data were collected until 29 February 2020 and the median follow-up was 7·3 years 
(interquartile range 7·1 to 7·6). The total follow-up was 14 071·4 person-years in the 
screening arm and 13 921·6 person-years in the control arm. For the screening arm, the 
median follow-up from last UKLS LDCT is 7.0 years (interquartile range 6.2 to 7.3). 
In that period, 76 lung cancer deaths were recorded (30 in the screening arm and 46 in the 
control arm). The primary analysis showed that this difference was not statistically significant 
(RR 0·65 [95% CI 0·41–1·02]; p=0·062). The cumulative mortality graph is given in Figure 
2. There were no significant differences in lung cancer mortality in the male (RR 0·63 [95% 
CI 0·37–1·08]; p=0·091) and female (RR 0·69 [95% CI 0·28–1.69]; p=0·419) subgroups. 
When analysis was repeated on a per-protocol basis, to assess the impact of the 33 individuals 
allocated to the screening arm who did not in fact undergo CT screening, a similar result (RR 
0·67 [95% CI 0·42–1·05]; p=0·082) was observed. 
There was a total of 512 deaths from any cause during the follow-up period (246 in the 
screening arm and 266 in the control arm), a difference which was not significant (RR 0·91 
[0·77–1·09]; p=0·315). There was also no significant difference in mortality from any cancer 
(118 deaths in the screening arm and 125 in the control arm; RR 0·93 [0·73–1·20]; p=0·594), 
or in mortality from causes other than lung cancer (216 in the screening arm and 220 in the 
control arm; RR 0·97 [0·81–1·17]; p=0·762). 
Lung cancer incidence was collected until 31 December 2019 and the median follow-up was 
7·2 years (interquartile range 7·0 to 7·5). The total follow-up was 13 493·8 person-years in 
the screening arm, and 13 539·1 person-years in the control arm. 
A total of 161 lung cancers were diagnosed in that period (86 in the screening arm and 75 in 
the control arm). This difference in incidence by trial arm was not statistically significant (RR 
1·15 [0·84–1·57]; p=0·375). The cumulative incidence graph is given in Figure 3. There was 
a non-significant increase in incidence of 7% for males (RR 1·07 [0·75–1·54]; p=0·702), and 
of 41% for females (RR 1·41 [0·76–2·59]; p=0·274); further results by sex are provided in 




Of the 161 participants diagnosed with lung cancer, a total of 100 died (from any cause). The 
number of deaths among participants in the screening arm was significantly lower than in the 
control arm, at 42 compared to 58 (RR 0·52 [0·35–0·77]; p=0.001). The cumulative mortality 
graph is given in Figure 4. The difference was also significant for males (RR 0·52 [0·32–
0·82]; p=0·005), but not for females (RR 0·53 [0·24–1·16]; p=0·112). 
There were 12 deaths in each arm from causes other than lung cancer, among those diagnosed 
with lung cancer. This difference was not significant (RR 0·72 [0·32–1·60]; p=0·416). 
The stage distribution of lung cancers shown in Table 2, indicated a higher proportion of 
early-stage disease in the screening arm (Pearson’s chi-squared = 30.16, p<0·001). The odds 
of a cancer being diagnosed at a late stage (stage III or IV) were significantly lower in the 
screening arm than in the control arm (odds ratio 0·14 [95% CI 0·07–0·32]; p<0·001). 
Overall, there were significantly fewer late-stage lung cancers in the screening arm compared 
to the control arm, at 16 vs 37 (RR 0·43 [0·24–0·77]; p=0·005). The cumulative incidence of 
stage III/IV lung cancers is shown as Figure 5. 
Analysis was carried out to explore the histological types of the lung cancers diagnosed, with 
the outcomes being shown in Table 3. There was no significant difference between the two 
arms (Pearson’s chi-squared = 8·68, p=0·070). 
For those in the screening arm, Table 4 sets out the number of cancers diagnosed for each 
nodule classification category, and the time at which they were detected. Figure 6 shows the 
cumulative incidence for each category, for those cancers which were not screen-detected 
(i.e. detected at UKLS baseline or follow-up LDCT scans). The risk for those in Category 3 
was more than six times that of those in Category 1 (RR 6·29 [95% CI 2·81–14·06]; 
p<0.001), and for those in Category 4 it was more than twelve times greater (RR 12·29 
[3·26–46·32]; p<0.001). 
Figure 3 suggests that the cumulative incidence in the two arms begins to converge after five 
years. This is also the period with regard to which the LLP risk (used as one of the eligibility 
criteria) is calculated. However, a post-hoc analysis showed that the difference up to that 
point was not significant (67 lung cancers in the screening arm compared to 52 in the control 
arm, RR 1·30 [0·90–1·86]; p=0·162). 
Results from nine randomised controlled trials were included in the meta-analysis 
(Supplementary Appendix; literature search, PRISMA flow diagram, characteristic of 
included studies and risk of bias assessment). LDCT screening was associated with a 16% 




(RR 0·84 [0·76 – 0·92]) with no significant heterogeneity (p= 0·31, I2=14·2%) as shown in 
Figure 7. A small relative reduction in all-cause mortality was observed (RR 0·97 [0·94 – 
1·00]) with no heterogeneity (p=0·61, I2=0·0%) as shown in Figure 8. There was no 
statistically significant evidence (p=0·47, Poisson regression interaction test) of a differential 
effect on lung cancer mortality by sex in the available, published randomised trial data.  
 
DISCUSSION 
The UKLS trial has seven years’ follow-up outcome data providing lung cancer mortality 
results which while not statistically significant (RR 0·65 [95% CI 0·41–1·02]; p=0·062) (Fig 
2) are consistent with the findings from other trials of a substantial reduction in lung cancer 
mortality. During the follow-up period, there were a total of 512 deaths from any cause (246 
in the screening arm and 266 in the control arm), a difference which was not significant (RR 
0·91 [0·77–1·09]). 
The results from nine randomised controlled trials, including the UKLS trial, were included 
in the meta-analysis, which demonstrated a 16% relative reduction in lung cancer mortality, 
in the LDCT arm, when compared against a non-LDCT control arm (RR 0·84 [0·76 – 0·92]) 
with no significant heterogeneity (p= 0·31, I2=14·2%). A small relative reduction in all-cause 
mortality was also observed (RR 0·97 [0·94 – 1·00]). 
The fundamental basis on which one undertakes lung cancer screening is to identify early 
lung cancer when it is still readily curable. The UKLS successfully provided evidence 
indicating a higher proportion of early-stage disease associated with LDCT screening 
(p<0·001). No significant difference was observed by UKLS trial arm in terms of histological 
type (Pearson’s chi-squared 8·68, p=0·070), with the majority being non-small cell lung 
cancer. There was an association between nodule size at baseline and relative risk of lung 
cancer during the follow-up period. 
The UKLS results are consistent with the findings of the NLST5 and NELSON6 trials, 
however, the uniqueness of the UKLS lies in the fact that it was the only lung cancer CT 
RCT to utilise a formal, multivariate lung cancer risk prediction model to select high risk 
participants (4.5% risk over five year 23,24).  
The UKLS Wald Single Screen design resulted in diagnosis of lung cancer with 67% at stage 
1 and 83% suitable for surgical intervention.21 The intervention had no long-term 
psychological impact, successfully integrated smoking cessation and was considered cost 




of lung cancer LDCT screening beyond the initial screen. Figure 2 demonstrates the benefit 
in terms of lung cancer mortality with the difference emerging most strongly in years 3-6 
after randomisation and continuing for the seven year follow-up period. Figure 3 
demonstrates the benefit of early detection is maintained beyond five years after 
randomisation. The UKLS trial, demonstrating long-term benefit from a single screen, 
provides potentially important data for inclusion in future modelling studies to optimise the 
screening interval. 
The potential difference in effectiveness of screening between males and females is an issue 
of interest. The NELSON trial found a larger reduction in mortality in the small population of 
females, not significant at ten years follow-up, but significant at earlier time points. Similar 
results have been seen (albeit non-significant) in the NLST and the German LUSI Trial. 
Although this finding was not seen in the UKLS results, possibly due to small numbers, the 
differential effect by sex clearly requires further research. 
Overdiagnosis is a potential issue in all cancer screening programmes, as well as in lung 
cancer CT screening;28 Overdiagnosis is defined as the diagnosis of cancer, histologically 
confirmed, as a result of screening, which would never have been diagnosed in the host’s 
lifetime if screening had not taken place.  NELSON reported 8.9% overdiagnosis,6 the NLST 
initially reported 18%,28 however, more recent follow-up has suggested only a 3% 
overdiagnosis in the LDCT arm.29 Estimates from the other trials vary considerably.12,30 In 
the UKLS the “absolute incidence” after a median follow-up of 7·2 years (Figure 3, 75 vs 86 
cases) indicates a potential 15% excess incidence in the lung cancer screening arm, which 
represents an estimate of the worst-case scenario for over-diagnosis, since screening stopped 
after the single screen.  The MISCAN lung cancer model estimated overdiagnosis to be 10% 
in screened populations31.  
While UKLS results are not statistically significant, there is sufficient follow-up to include in 
a meta-analysis together with the eight other previously reported randomised controlled trials. 
Our updated meta-analysis provides conclusive evidence of a reduction in lung cancer 
mortality with LDCT screening (0·84 [95% CI 0·76-0·92]) (Figure 7). This meta-analysis 
also included the USA LSS trial, as well as utilising the NELSON male and female mortality 
data, and the updated NLST report.29 The results strengthen recently reported meta-analyses 
of lung cancer screening indicating consistent and robust evidence overall.32,33 Despite 




Worldwide evidence searches indicate that there are a number of lung cancer CT screening 
trials in China.34  only one of which to date has published initial outcome data, but this was 
not included in our meta-analysis as it has not reported long-term follow-up data.35 
No one trial was designed with the intention of demonstrating a reduction in all-cause 
mortality. It is appreciated that over 100 000 individuals would be required to achieve such 
an objective. The meta-analysis here presented includes data from 94 834 individuals across 
the nine RCTs with a small reduction in all-cause mortality (RR 0·97 [0·94 – 1·00]) (Figure 
8). However, even a small reduction in all-cause mortality as shown here, does represent a 
large number of lives should countries around the world adopt lung cancer screening 
programmes. It is also consistent with the proportion of deaths from lung cancer in the trial 
populations.  
To follow precedent and to demonstrate even-handedness, the meta-analysis used the most 
recent primary reported mortality results from the randomised trials. It should be noted, 
however, that this is conservative, since the most recent reported results include deaths from 
lung cancers diagnosed after the screening phase of the trials and when both trial groups were 
receiving usual care. While this does not affect the absolute benefit, it dilutes the relative 
effect of the intervention, conservatively biasing the RR of lung cancer mortality towards 
unity. In the breast and bowel screening trials, this bias is avoided by including only deaths 
(whenever they occur) from cancers diagnosed during the screening phase of the trials.36,37  
Duffy and Smith 36 show that this bias is reduced but estimates remain slightly conservative 
when analysis is restricted to cancers diagnosed during the screening phase. The NLST 
publication reporting the RR of 0.92 of deaths from lung cancer diagnosed up to 12 years 
after randomisation (9 years after the screening phase ended), also reported a secondary 
analysis including only deaths from lung cancers diagnosed up to 6 years after randomisation, 
giving a RR of 0.89.29 Thus, the relative benefit is likely to be underestimated in the meta-
analysis. 
The number of individuals recruited into the UKLS pilot trial is its major limitation when 
considering the effect on lung cancer mortality. Pragmatically, we relied on nationally 
curated data (ONS) rather than having a cause of death committee. This, however, does mean 
that the cause of death was determined in the absence of knowledge of which trial group the 
subjects belonged to. UKLS predates introduction of British Thoracic Society pulmonary 
nodule guidelines.38 but utilised similar nodule categorization to NELSON. However, the trial 




high risk individuals, the identification of early-stage disease and the number of individuals 
suitable for surgical intervention.21 Its contribution to the overall meta-analysis adds to the 
consistency of evidence internationally. 
Lung cancer screening has been implemented in the USA through funding from MEDICARE 
but uptake has been low (~ 4%).39 Lung cancer CT screening implementation programmes 
incorporating risk model based LDCT screening are well underway in the UK; led by the 
Liverpool Health Lung Project (LHLP),40 followed by Manchester,41 Yorkshire ,42 West 
London43 and now the NHS England Targeted Healthy Lung Checks Programme.44 The 
targeted approach in the UK has resulted in higher participation rates (40% - 53%).40,45 
In conclusion the meta-analysis incorporating the results from nine RCTs provides further 
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Sex#   
Male 1529 (75%) 1507 (74%) 
Female 499 (25%) 520 (26%) 
Median age# at date of consent 68 (IQR 65-71) 68 (IQR 65-71) 
Age 50-59 44 (2%) 58 (3%) 
Age 60-69 1295 (64%) 1291 (64%) 
Age 70-76 689 (34%) 678 (33%) 
Median IMD Rank 17374 17704 
Median LLPv2 score (IQR) 7·11 (5·58 – 10·08) 7·35 (5·59 – 10·08) 
Smoking history   
Never smokers 2 (0%) 0 (0%) 
Current smokers 777 (38%) 791 (39%) 
Ex-smokers 1249 (62%) 1236 (61%) 
Smoking duration ‡#   
10-19 years 117 (6%) 116 (6%) 
20+ years 1895 (93%) 1907 (94%) 
Unknown 14 (1%) 4 (0%) 
Asbestos exposure # 763 (38%) 763 (38%) 
History of respiratory disease *# 1056 (52%) 1023 (50%) 
History of solid tumour **# 378 (19%) 396 (20%) 
Family history of lung cancer# 498 (25%) 554 (27%) 
Early onset (before age 60) 215 (11%) 215 (11%) 
Late onset (on or after age 60) 283 (14%) 339 (17%) 
‡ All smoking duration figures refer to current- and ex-smokers combined 
*asthma, bronchitis, TB, pneumonia, COPD, or emphysema 
**cancers of brain, head & neck, oesophagus, breast, colon or "other" 
# these factors contribute to the LLP risk score 











Control Total (%) 
IA 22 (52.4) 15 (53.6) 37 (52.9) 8 (14.5) 
IB 5 (11.9) 3 (10.7) 8 (11.4) 4 (7.3) 
IIA 7 (16.7) _ 7 (10.0) 4 (7.3) 
IIB 1 (2.4) 1 (3.6) 2 (2.9) 2 (3.6) 
IIIA 5 (11.9) 2 (7.1) 7 (10.0) 4 (7.3) 
IIIB  (0) 2 (7.10 2 (2.9) 6 (10.9) 
IV 2 (4.8) 5 (17.9) 7 (10.0) 27 (49.1) 
NA 
 
16 16 20 
Total 42 44 86 75 
*TNM version 7 staging; NA= not available from NCRAS, e.g. not staged (n=4) or 
during 2018-2019 (staging data not released at time of analysis, n=33); % refers to 
cancers with known staging only 
 
Table 3 Lung cancers by histological type – number (percentage) 





Adenocarcinoma 25 (59.5) 19 (43.2) 44 (51.2) 26 (34.7) 
Squamous cell 
carcinoma 
12 (28.6) 7 (15.9) 19 (22.1) 18 (24) 
NSCLC NOS* 0 (0) 1 (2.3) 1 (1.2) 2 (2.7) 
Small cell carcinoma 3 (7.1) 6 (13.6) 9 (10.5) 8 (10.7) 
Carcinoid/ Large Cell 1 (2.4) 0 (0) 1 (1.2) 4 (5.3) 
NOS 1 (2.4) 11 (25.0) 12 (14.0) 17 (22.7) 
Total 42 44 86 75 














Lung cancer detected at: 
Baseline 3m FU 12m FU 1-2y 2-5y >5y 
1 963 (49.3) 8 (0.8%) - - - 3 0 5 
2 469 (24.0) 9 (1.9%) - - 1 1 3 4 
3 458 (23.4) 32 (7.0%) - 2 7 0 14 9 
4 64 (3.3) 35 (54.7%) 32 - - 2 1 0 
All 1954 84* 32 2 8 6 18 18 
UKLS Pulmonary Nodule categories described in Supplementary materials; Note: All subjects 
with Category 4 nodules investigated clinically after baseline; those with Category 3 nodules 
had follow up scan (FU) at 3 and 12 months (m); those with Category 2 nodules had FU at 
12m; Category 1 subjects (nodules < Category 2 or no nodules detected) had no FU. * Data 
not available for 2 cancers diagnosed in CT screening arm as amongst the 34 subjects who 




Figure 1: Trial profile 
Figure 2: Cumulative mortality from lung cancer
Figure 3: Cumulative incidence of lung cancer
Figure 4: Cumulative mortality from all causes (participants diagnosed with lung cancer)
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Figure 5: Cumulative incidence of late stage lung cancer
Figure 6: Cumulative incidence of lung cancer by nodule classification category (screening
arm only, excluding screen-detected cancers)
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Figure 7: Forest plot, lung cancer mortality
Figure 8: Forest plot, mortality from all causes
